Diagnostic performance of 18F-choline PET-CT in prostate cancer.
Pilar SamperA Luis CardoC Vallejo OcañaM A Cabeza RodríguezL A Glaria EnríquezM L Couselo PaniaguaJ Olivera VegasPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2018)
These findings support the clinical use de 18F-choline PET-CT in staging high-risk patients with a secondary Gleason ≤ 4 and GS ≤ 7, in restaging patients with biochemical recurrence after RP if PSA at failure ≥ 1.37 ng/ml or PSADT ≤ 4 months and in patients with biochemical failure after RT, if PSADT ≤ 4.6 months and time to failure < 5 years, because it determines a change in the therapeutic indication.